Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoCHGCF -7.28%85 3-Year ROIIC % is 27.70 as of Dec. 2025, which is 20% below its 10-year median of 34.63. GuruFocus rates CHGCF with a GF Score™ of 85/100 and a GF Value™ of $49.32 (Fairly Valued). The stock has 1 warning sign investors should review. Among 946 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 75.79% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Chugai Pharmaceutical Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 27.70%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Chugai Pharmaceutical Co's 3-Year ROIIC % or its related term are showing as below:
CHGCF's 3-Year ROIIC % is ranked better than 75.79% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs CHGCF: 27.70
Chugai Pharmaceutical Co (OTCPK:CHGCF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Chugai Pharmaceutical Co 3-Year ROIIC % Related Terms
Chugai Pharmaceutical Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHGCF vs LLY, JNJ, ABBV: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Chugai Pharmaceutical Co (CHGCF) has a 3-Year ROIIC % of 27.70 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Chugai Pharmaceutical Co and its competitors. This is 20% below median its historical median of 34.63. Over the past decade, Chugai Pharmaceutical Co's 3-Year ROIIC % has ranged from 2.40 to 115.84. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #229 out of 946 companies in the Drug Manufacturers industry, placing it in the top 24.2%.
Is Chugai Pharmaceutical Co's 3-Year ROIIC % too high?
Chugai Pharmaceutical Co's current 3-Year ROIIC % of 27.70 is 20% below median its 10-year median of 34.63. Over the past 10 years, this metric has ranged from a low of 2.40 to a high of 115.84. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Chugai Pharmaceutical Co's value of 27.70 is 644.6% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #229 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chugai Pharmaceutical Co has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's 3-Year ROIIC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #229 out of 946 companies for 3-Year ROIIC %. This places Chugai Pharmaceutical Co in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.72. Chugai Pharmaceutical Co's value of 27.70 is 644.6% above this benchmark. Historically, Chugai Pharmaceutical Co's own 3-Year ROIIC % has ranged from 2.40 to 115.84 over the past decade. While the company's 10-year median is 34.63 vs. the industry median of 3.72, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current 3-Year ROIIC % of 27.70 is 644.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current 3-Year ROIIC % is 27.70, which is 20% below median its own 10-year median of 34.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCF) is currently considered Fairly Valued. The stock's GF Value™ is $49.32, compared to a current price of $43.18 — trading 12.4% below its estimated fair value. The current 3-Year ROIIC % is 27.70, which is 20% below median its 10-year median of 34.63 and 644.6% above the Drug Manufacturers industry median of 3.72. Chugai Pharmaceutical Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCF), the current 3-Year ROIIC % is 27.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (CHGCF) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of $43.18 is trading 12.4% below its estimated GF Value™ of $49.32.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for CHGCF:
3-Year ROIIC %: 27.70 (20% below median its 10-year median of 34.63)
GF Value™: $49.32 vs. price of $43.18 (12.4% below fair value)
Industry Position: 644.6% above the Drug Manufacturers median (#229 of 946)
No single metric tells the full story. See the CHGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
85GF Score
Get the complete analysis for CHGCF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHGCF has been successfully added to your 
